Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2011-01-19 Capital/Financing Update
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
424(B)(5)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an offering of common stock and warrants by pSivida Corp. It details the terms of the securities offering, use of proceeds, risk factors, and other related information typical of a capital raising document. It is not a financial report, earnings release, or management discussion, but rather a detailed disclosure document for a securities offering. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities.
2011-01-19 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce specific events or updates. The text indicates it is reporting an event on December 23, 2010, specifically a press release about a Complete Response Letter from the FDA related to a drug application. The document is short (2384 characters) and primarily serves to announce this event and attach the press release as an exhibit. There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Earnings Release, or Legal Proceedings Report. Therefore, the correct classification is Regulatory Filings (RNS).
2010-12-28 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content focuses on the employment agreement and appointment of Leonard S. Ross as Vice President, Finance, including details of his compensation and severance terms. This corresponds to an announcement of changes in senior management. There are no financial statements or earnings data presented, so it is not an earnings release or financial report. The document fits the category of Board/Management Information (MANG) as it announces a management appointment and related agreements.
2010-12-21 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 9, 2010, for pSivida Corp. The key content is the submission of matters to a vote of security holders at the annual meeting, including election of directors, approval of stock option grants, and ratification of the appointment of the independent auditor. The document provides detailed voting results for these proposals. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document is not an annual report, earnings release, or proxy statement, but specifically reports voting outcomes. The length is under 5,000 characters but contains substantive voting data, so it is not a mere announcement of a report. Therefore, the correct classification is DVA with high confidence.
2010-12-13 English
FORM 4
Director's Dealing
2010-12-10 English
FORM 4
Director's Dealing
2010-12-10 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.